drugset / Trial / NCT01313065
Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of IV administration of VX15/2503 in patients with advanced solid tumors. The escalation part of the study will determine the maximum tolerated dose (MTD).
Timeline
- Start
- 2011-01
- Primary completion
- 2014-06
- Completion
- 2014-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pepinemab | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | Pepinemab | Monoclonal antibody | 20 mg/kg | Intravenous |